News – Page 1095 – Endpoints News

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

8 years ago

We've taken a big step forward at Endpoints News — and with your help, we'll make more strides

8 years ago

Sanofi/Regeneron win a new trial on Praluent patents; BridgeBio bankrolls $30M biotech startup

8 years ago

Acadia adopts a new PhIII game plan for 'breakthrough' med, dumps Alzheimer's PhII

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Bluebird’s gene therapy shows promise in keeping lethal Lorenzo’s Oil disease in check

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Faster, pricier and often worthless: Study slams regulators for wave of questionable cancer drug OKs

8 years ago

Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open

8 years ago

Congress fires another salvo at Allergan’s Mohawk deal; AI outfit raises $60M for discovery effort

8 years ago

FDA offers surprise OK for Mylan’s Copaxone knockoffs, slamming Teva

8 years ago

What failure? Catabasis shares soar after execs tout open-label data, PhIII plans

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

Following FDA debacle in ’09, Motif lines up a new shot at approval for antibiotic iclaprim

8 years ago

Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch

8 years ago

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

8 years ago

Amgen comes up with $1.5B package to partner with CytomX on a preclinical Probody approach to cancer

8 years ago

Dear Kite: With 2300% upside, we blazed an amazing trail

8 years ago

Patients often demand experimental drugs that prove ineffective — report

8 years ago

Hot on heels of a positive PhIII, Ablynx files $150M IPO; Shire sues Allergan over dry eye drug rivalry

8 years ago

Shoving Regenxbio aside, Ultragenyx’s Emil Kakkis closes Dimension buyout deal with 400% premium

8 years ago

Pushing the positive in p=0.05, RedHill says it’s ready for a pivotal IBD test

8 years ago

On a roll, Rigel flags a positive PhII for its lead, late-stage drug fostamatinib

8 years ago

Celgene joins the heavyweight partner club collaborating with Nimbus

8 years ago

First page Previous page 1092 1093 109410951096 1097 1098 Next page Last page